PL405115A1 - Aptamers having affinity to MDM2 protein, their compositions and the use thereof - Google Patents
Aptamers having affinity to MDM2 protein, their compositions and the use thereofInfo
- Publication number
- PL405115A1 PL405115A1 PL405115A PL40511513A PL405115A1 PL 405115 A1 PL405115 A1 PL 405115A1 PL 405115 A PL405115 A PL 405115A PL 40511513 A PL40511513 A PL 40511513A PL 405115 A1 PL405115 A1 PL 405115A1
- Authority
- PL
- Poland
- Prior art keywords
- aptamers
- affinity
- mdm2 protein
- compositions
- mdm2
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Wynalazek dotyczy aptamerów stanowiących cząsteczki DNA posiadające powinowactwo do białka MDM2 oraz kompozycji zwierających aptamery. Wynalazek obejmuje także zastosowania aptamerów do wytwarzania leku do zwalczania chorób nowotworowych oraz do zastosowania do diagnostyki. Ujawniona w ramach wynalazku sekwencja nukleotydowa aptamerów oraz jej kompozycje wykazują właściwości specyficznego wiązania białka MDM2, które umożliwia antagonizowanie wiązania MDM2-p53 oraz zabijanie lub hamowanie wzrostu komórek nowotworowych.The invention relates to aptamers constituting DNA molecules having affinity for MDM2 protein and compositions containing aptamers. The invention also includes the use of aptamers for the manufacture of a medicament for combating cancer and for use in diagnostics. The aptamer nucleotide sequence disclosed in the context of the invention and its compositions exhibit MDM2 protein specific binding properties that allow antagonizing MDM2-p53 binding and killing or inhibiting tumor cell growth.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL405115A PL227370B1 (en) | 2013-08-22 | 2013-08-22 | Aptamers having affinity to MDM2 protein, their compositions and the use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL405115A PL227370B1 (en) | 2013-08-22 | 2013-08-22 | Aptamers having affinity to MDM2 protein, their compositions and the use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
PL405115A1 true PL405115A1 (en) | 2014-06-09 |
PL227370B1 PL227370B1 (en) | 2017-11-30 |
Family
ID=50846671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL405115A PL227370B1 (en) | 2013-08-22 | 2013-08-22 | Aptamers having affinity to MDM2 protein, their compositions and the use thereof |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL227370B1 (en) |
-
2013
- 2013-08-22 PL PL405115A patent/PL227370B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL227370B1 (en) | 2017-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123355T1 (en) | ANTIBODIES TO CD73 AND USES THEREOF | |
PH12018500906A1 (en) | Antibodies specifically binding pd-1 and their uses | |
CY1121517T1 (en) | NON-FUCUCYLIZED ANTIBODIES ENANTI-FGFR2IIIB | |
CY1120035T1 (en) | Pyrimidopyrimidinones usable as suspensions of WEE-1 kinase | |
CL2017001459A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
EA201890754A1 (en) | CONNECTIONS AND METHODS OF THEIR APPLICATION | |
UA117364C2 (en) | Amatoxin derivatives | |
MX2016003843A (en) | Irak inhibitors and uses thereof. | |
MX2021007663A (en) | Target-tissue-specific antigen-binding molecule. | |
MX2015013163A (en) | Multivalent and monovalent multispecific complexes and their uses. | |
EA201590997A1 (en) | CONNECTIONS AND METHODS OF THEIR APPLICATION | |
MX2014009289A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer. | |
EA201590085A1 (en) | ANTIBODIES ANTI-EGFR AND THEIR APPLICATION | |
NZ739622A (en) | Antibodies to tau | |
TR201903009T4 (en) | Exon skipping compositions for the treatment of muscular dystrophy. | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
EA201490826A1 (en) | ACC INHIBITORS AND THEIR APPLICATIONS | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
MX2021010668A (en) | Cytokine fusion proteins. | |
EA201492056A1 (en) | Pyrimidinyl inhibitors of tyrosine kinase | |
WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
MX2015011518A (en) | Met-binding agents and uses thereof. | |
MX2022006304A (en) | Compositions and methods for inhibiting the biological activity of soluble biomolecules. | |
MY165075A (en) | Pharmaceutical composition comprising fimasartan and hydrochlorothiazide |